Findings

What do systematic reviews say?

3 questions · 3 findings · 1 reviews · Gynaecological, Neuro-oncology and Orphan Cancer

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 33.3%Low 1 · 33.3%Moderate 1 · 33.3%High 0 · 0%

Summary of findings 1: PLD with chemotherapy vs PLD alone

Progression‐free survival · recurrent platinum‐resistant EOC

Summary of findings 3: PLD with chemotherapy showed no clear difference in progression‐free survival (PFS) compared with PLD alone (low certainty).

1 finding from 1 review

Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
HR 0.94 [0.73, 1.22]
2 studies · 353 participants
Low

Summary of findings 1: PLD with chemotherapy vs alternative combination chemotherapy

Progression‐free survival · platinum‐sensitive recurrent EOC

Summary of findings 1: PLD with chemotherapy probably leads to lower progression‐free survival (PFS) compared with alternative combination chemotherapy (moderate certainty).

1 finding from 1 review

Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
HR 0.81 [0.74, 0.89]
5 studies · 2006 participants
Moderate

Summary of findings 2: PLD alone vs other conventional chemotherapy

Progression‐free survival · recurrent platinum‐resistant EOC

It is very uncertain whether summary of findings 2: PLD alone changes progression‐free survival (PFS) compared with other conventional chemotherapy (very low certainty).

1 finding from 1 review

Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
HR 0.94 [0.85, 1.04]
4 studies · 1803 participants
Very low